Analysis of Hypotheses

HbA1c Response

The primary outcome for the TIAD study is change in HbA1c level from baseline to week 48 in the intent-to-treat (ITT) population. In this analysis, we will include 283 patients, 137 in the placebo arm, and 146 in the athelis arm. Of the 286 randomized as shown in Figure 1, three HbA1c baseline results are missing in the placebo arm and must be excluded. Two were randomized but dropped out of the trial before blood was drawn. One is missing due to a lab error. The median follow-up time in both groups is 48 weeks with a minimum of 0 and a maximum of 48.
  • We will use a repeated measures mixed model as described above.
  • Tables 12.3 and 12.4 below show the information we will present.
  • We will ...

Get Data Analysis Plans: A Blueprint for Success Using SAS now with O’Reilly online learning.

O’Reilly members experience live online training, plus books, videos, and digital content from 200+ publishers.